Loading…
Lobbying Spend
—
Filings
109
Firms Hired
2
Active Period
2008–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
H.R.5269/S.2761 - RESULTS Act Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Proposed Rule (CMS-1850-P) CY 2027 Payment Policies under the Medicare Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies (CMS-1848-P)
Client expense: — · Firm income: $70,500
Matched citations: H.R.5269
H.R.5269/S.2761 - RESULTS Act Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Proposed Rule (CMS-1850-P) CY 2027 Payment Policies under the Medicare Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies (CMS-1848-P)
Client expense: — · Firm income: $70,500
Matched citations: S.2761
Patent Eligibility Restoration Act of 2025
2026 · second_quarter · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Client expense: — · Firm income: $70,500
Matched citations: H.R.3152
H.R.5269/S.2761 - RESULTS Act
Client expense: — · Firm income: $70,500
Matched citations: H.R.5269
H.R. 8890: Enhancing CLIA Act of 2026
Client expense: — · Firm income: $70,500
Matched citations: H.R. 8890
Patent Eligibility Restoration Act of 2025
2026 · second_quarter · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Client expense: — · Firm income: $70,500
Matched citations: S.1546
H.R.5269/S.2761 - RESULTS Act
Client expense: — · Firm income: $70,500
Matched citations: S.2761
Patent Eligibility Restoration Act of 2025
2026 · first_quarter · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Client expense: — · Firm income: $70,500
Matched citations: H.R.3152
P.L. 113-93, Protecting Access to Medicare Act H.R.5269/S.2761 - RESULTS Act CRUSH Request for Information Request for Information: Accelerating the Adoption and Use of Artificial Intelligence as Part of Clinical Care
Client expense: — · Firm income: $70,500
Matched citations: H.R.5269
Patent Eligibility Restoration Act of 2025
2026 · first_quarter · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Client expense: — · Firm income: $70,500
Matched citations: S.1546
P.L. 113-93, Protecting Access to Medicare Act H.R.5269/S.2761 - RESULTS Act CRUSH Request for Information Request for Information: Accelerating the Adoption and Use of Artificial Intelligence as Part of Clinical Care
Client expense: — · Firm income: $70,500
Matched citations: S.2761
Patent Eligibility Restoration Act of 2025
2025 · fourth_quarter · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Client expense: — · Firm income: $70,500
Matched citations: H.R.3152
P.L. 113-93, Protecting Access to Medicare Act H.R.5269/S.2761 - RESULTS Act
Client expense: — · Firm income: $70,500
Matched citations: H.R.5269
Patent Eligibility Restoration Act of 2025
2025 · fourth_quarter · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Client expense: — · Firm income: $70,500
Matched citations: S.1546
P.L. 113-93, Protecting Access to Medicare Act H.R.5269/S.2761 - RESULTS Act
Client expense: — · Firm income: $70,500
Matched citations: S.2761
Patent Eligibility Restoration Act of 2025
2025 · third_quarter · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Client expense: — · Firm income: $70,500
Matched citations: H.R.3152
Patent Eligibility Restoration Act of 2025
2025 · third_quarter · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Client expense: — · Firm income: $70,500
Matched citations: S.1546
To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes.
2025 · second_quarter · Firm: IPOLICY SOLUTIONS
No bill #: legislation to clarify CLIA FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests" HR 1463: Freedom for Laboratory Innovation and Testing Act
Client expense: — · Firm income: $70,500
Matched citations: HR 1463
Patent Eligibility Restoration Act of 2025
2025 · second_quarter · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Client expense: — · Firm income: $70,500
Matched citations: H.R.3152
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
2025 · second_quarter · Firm: IPOLICY SOLUTIONS
H.R.4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client expense: — · Firm income: $70,500
Matched citations: H.R.4121
Patent Eligibility Restoration Act of 2025
2025 · second_quarter · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Client expense: — · Firm income: $70,500
Matched citations: S.1546
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
2025 · second_quarter · Firm: IPOLICY SOLUTIONS
No bill #: legislation to clarify CLIA FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests" HR 1463: Freedom for Laboratory Innovation and Testing Act
Client expense: — · Firm income: $70,500
Matched citations: S.J.Res.82
To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes.
2025 · first_quarter · Firm: IPOLICY SOLUTIONS
No bill #: legislation to clarify CLIA FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests" HR 1463: Freedom for Laboratory Innovation and Testing Act
Client expense: — · Firm income: $70,500
Matched citations: HR 1463
Right Drug Dose Now Act of 2025
2025 · first_quarter · Firm: IPOLICY SOLUTIONS
HR 2471: Right Drug Dose Now Act
Client expense: — · Firm income: $70,500
Matched citations: HR 2471
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
2025 · first_quarter · Firm: IPOLICY SOLUTIONS
No bill #: legislation to clarify CLIA FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests" HR 1463: Freedom for Laboratory Innovation and Testing Act
Client expense: — · Firm income: $70,500
Matched citations: S.J.Res.82
Source: Senate LDA